MedTrace Logo

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

NCT00525616 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-16

No results posted yet for this study

Summary

The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.

Conditions

  • Bullous Pemphigoid

Interventions

DRUG

Mabthera

Two IV perfusions of 1000mg at 15 days intervals

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Pascal JOLY, MD-PHD · Clinique Dermatologique - Hôpital Charles Nicolle

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525616 on ClinicalTrials.gov